Navigation Links
A turn-off for cancer

Although plants and animals are very different organisms, they share a surprising number of biological mechanisms. A plant biologist at Tel Aviv University says that one of these mechanisms may be the answer for turning off cancer growth in humans.

Prof. Shaul Yalovsky, of the Molecular Biology and Ecology of Plants Department at Tel Aviv University, has identified a "switch" that can turn on cell growth in plants. Now, in a laboratory setting, he can apply the mechanism to reshape cells, grow new tissues, and respond to bacterial or viral invaders.

The switch is actually a fat molecule that modulates a group of proteins called ROPs. Reported in the scientific journal Current Biology, Prof. Yalovsky's research group, in collaboration with Prof. Yoav Henis and Dr. Joel Hirsch of TAU's Departments of Neurobiology and Biochemistry, has determined that this fat molecule is required for ROP activity. Proteins very similar to ROPs exist in humans and provide chemical signals that tell cancer when to metastasize. Now that they know how to regulate ROPs in plants, the researchers believe they are one step away from turning this ROP-like switch off in humans a process which could prevent tumor growth.

An ancient secret revealed

"We've stumbled upon an ancient mechanism that regulates the function of these proteins, proteins which are found in both plants and humans," says Prof. Yalovsky, explaining that this mechanism already regulates the immune response to pathogen invaders in the human body. ROP-like proteins are also involved in wound healing and development of nerve cells in the brain.

"When these proteins are turned 'on,' they can initiate processes like cell division and growth," says Prof. Yalovsky. "Through our genetic engineering, these proteins could be manipulated in humans to speed up tissue healing, or turned off to slow or stop the growth of tumors."

ROPs bind to a small molecule called GTP, which then breaks up into another molecule called GDP. When bound to GDP, ROPs become inactive, a known concept in the plant sciences community. Going one step further, Prof. Yalovsky has created a second type of mutant molecule that prevents ROP proteins from binding to the GTP molecule, creating an inhibitory effect.

A new line of defense

The team's research could also be applied in agriculture to reduce the need for chemical pesticides, they say. The mutant molecule they've devised induces plants to respond as though they are being attacked by pathogens. They then create a biological defense that protects them from infection.

In the research paper, the Tel Aviv University scientists describe how these mutations and mechanisms work, providing a new mechanism to control metastasis in cancer, or stop the deterioration of certain nerve cells in the brain. And in a broader sense, the researchers have created a long-desired platform to test the function of proteins.

"It is common for plant and animal geneticists to identify proteins, but remain unaware of their functions. We now have a mechanism to test our hypotheses," adds Prof. Yalovsky.


Contact: George Hunka
American Friends of Tel Aviv University

Related medicine news :

1. Non-melanoma skin cancer may help identify survivors at increased risk for future cancers
2. Consortium seeks best treatment for HIV-positive cancer patients
3. Drug that helps metastatic colon cancer of no benefit in less advanced tumors
4. B2Discovery: Entrepreneurs and researchers join forces to conquer cancer
5. ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity
6. Molecular imaging detects recurrent prostate cancer
7. New treatment regimen shown effective against advanced ovarian cancer
8. Targeted Therapy Shows Promise Against Deadly Brain Cancer
9. Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
10. Researchers Report Treatment Headway Against Lung Cancer
11. Selenium shows no benefit in prevention of lung cancer
Post Your Comments:
Related Image:
A turn-off for cancer
(Date:12/1/2015)... ... December 01, 2015 , ... ... 7th Annual 2015 Golden Bridge Business Awards under the New Products and Services ... capex web based sample management software that helps labs organize data ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech North ... Gary has spent a significant amount of time in Sweden since joining PartnerTech ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani ... Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled ... Contact Center solutions targeted to the high-end enterprise contact center marketplace. , Ed ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a country ... drugs registered in Europe in 2015 were tested ... Russia has always been a country of choice ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: